Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Jun;170(6):1666-70; discussion 1670-1.
doi: 10.1016/s0002-9378(94)70338-8.

Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial

V L Seewaldt  1 , B E Greer, J M Cain, D C Figge, H K Tamimi, W S Brown, S A Miller
Affiliations
Clinical Trial

Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial

V L Seewaldt et al. Am J Obstet Gynecol. 1994 Jun.

Abstract

Objective: Our aim was to determine the efficacy and toxicity of paclitaxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer.

Study design: Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m2 over 24 hours every 21 days with optional granulocyte colony-stimulating factor support.

Results: Paclitaxel was generally well tolerated. In four patients bowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response.

Conclusion: A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.

PubMed Disclaimer

Publication types